Free shipping on all orders over $ 500

Monalizumab

Cat. No. M21501
Monalizumab  Structure
Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab can be used in the study of head and neck squamous cell carcinoma (HNSCC).

Chemical Information
CAS Number 1228763-95-8
Solubility (25°C) N/A
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jeongjae Lee, et al. J Cancer Res Clin Oncol. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines

[2] Roy S Herbst, et al. J Clin Oncol. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer

[3] Linda Borst, et al. Clin Cancer Res. The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment

[4] Thorbald van Hall, et al. J Immunother Cancer. Monalizumab: inhibiting the novel immune checkpoint NKG2A

[5] Pascale Andr, et al. Cell. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Related Products
AS 1411

AS1411 is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. AS1411 has anti-tumor activity.

MOMIPP 

MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB).

MOPIPP 

MOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog of MOMIPP. MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP also triggers methuosis, and interrupts glucose uptake and glycolytic metabolism. MOPIPP can cross the blood-brain barrier and shows efficacy in suppressing tumor progression agaisnt glioblastoma cells.

Methuosis inducer 1 

Methuosis inducer 1 is a potent methuosis inducer. Methuosis inducer 1 has anticancer activity.

Dextran (Mw 150000)

Dextran is a multipurpose branched glucan, which can improve plasma colloid osmotic pressure, increase blood volume, reduce platelet adhesion, inhibit red blood cell aggregation, reduce blood viscosity, reduce peripheral circulation resistance, and unclog microcirculation.

  Catalog
Abmole Inhibitor Catalog




Keywords: Monalizumab supplier, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.